Evaxion A/S (NASDAQ: EVAX), a clinical-stage TechBio company developing AI-Immunology™ powered vaccines, has appointed Dr. Helen Tayton-Martin as its new Chief Executive Officer. She will assume the role on November 24, 2025, and will simultaneously step down from the company’s Board of Directors. Dr. Tayton-Martin brings extensive leadership experience in biotechnology, holding a Ph.D. in molecular immunology and an MBA from London Business School. She co-founded Adaptimmune, a cancer-focused biotech firm, where she served as Chief Operating Officer and later Chief Business & Strategy Officer for 17 years. During her tenure, she led the company’s transatlantic expansion, secured multiple clinical, academic, and commercial partnerships, and oversaw financing efforts culminating in its Nasdaq IPO. She played a key role in strategic alliances with major pharmaceutical companies including Astellas, Genentech (a member of the Roche Group), GlaxoSmithKline, and Galapagos NV. Prior to Adaptimmune, she spent 15 years in various roles across the pharmaceutical, biotech, and consulting sectors. She also served as a non-executive director at Trillium Therapeutics Inc. from October 2017 until its acquisition by Pfizer Inc. in November 2021. Marianne Søgaard, Chairman of Evaxion’s Board, expressed enthusiasm about the appointment, highlighting Dr. Tayton-Martin’s proven track record in biotech leadership, partnerships, and value creation. She also thanked interim CEO Birgitte Rønø for her contributions during a pivotal period, noting that Rønø will now refocus on her role as Chief Scientific Officer, leading the company’s research and development efforts. Dr. Tayton-Martin expressed excitement about joining Evaxion, citing the strength of its AI-Immunology™ platform and recent milestones such as the out-licensing of EVX-B3 to MSD and compelling data for EVX-01 presented at ESMO. She emphasized her commitment to building on Evaxion’s scientific and commercial potential with the support of its talented team. Board Changes With her appointment as CEO, Dr. Tayton-Martin will leave the Board. Jens Bitsch-Norhave, a seasoned life sciences executive with over 25 years of experience in corporate strategy, global expansion, and dealmaking, will join the Board as an adviser and observer. He aims to seek election as a formal board member at the 2026 Annual General Meeting. Currently Corporate Vice President and Global Head of Corporate Development at Hengrui Pharmaceuticals, Bitsch-Norhave is responsible for strategy, business development, licensing, M&A, and alliance management. He holds an MSc and Ph.D. in neuropharmacology from the University of Copenhagen and an Executive MBA in Technology & Innovation from Copenhagen Business School. Evaxion continues to advance its AI-Immunology™ platform to develop novel immunotherapies for cancer, bacterial diseases, and viral infections. The company maintains a clinical-stage oncology pipeline of personalized vaccines and a preclinical infectious disease pipeline targeting areas with significant unmet medical needs.